Source:http://linkedlifedata.com/resource/pubmed/id/15888051
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-5-12
|
| pubmed:abstractText |
Modifications in the timing and dosage of immunosuppression can ameliorate the morbidity and mortality that has prevented widespread use of intestinal transplantation (ITx) in children. Thirty-six patients receiving ITx, aged 5 months to 20 years were given 2-3 mg(kg of rabbit anti-thymocyte globulin (rATG, thymoglobulin) just before ITx, and 2-3 mg(kg postoperatively (total 5 mg(kg). Twice daily doses of tacrolimus (TAC) were begun enterally within 24 h after graft reperfusion with reduction of dose quantity or frequency after 3 months. Prednisone or other agents were given to treat breakthrough rejection. After 8-28 months follow-up (mean 15.8 +/- 5.3), 1- and 2-year patient and graft survival is 100% and 94%, respectively. Despite a 44% incidence of acute rejection in the first month, 16 of the 34 (47%) survivors are on TAC (n = 14) or sirolimus (n = 2) monotherapy; 15 receive TAC plus low dose prednisone; one each receive TAC plus sirolimus, TAC plus azathioprine and TAC plus sirolimus and prednisone. There was a low incidence of immunosuppression-related complications. This strategy of immunosuppression minimized maintenance TAC exposure, facilitated the long-term control of rejection, decreased the incidence of opportunistic infections, and resulted in a high rate of patient and graft survival.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Azathioprine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1600-6135
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
5
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1430-6
|
| pubmed:dateRevised |
2010-12-3
|
| pubmed:meshHeading |
pubmed-meshheading:15888051-Adolescent,
pubmed-meshheading:15888051-Adult,
pubmed-meshheading:15888051-Animals,
pubmed-meshheading:15888051-Antilymphocyte Serum,
pubmed-meshheading:15888051-Azathioprine,
pubmed-meshheading:15888051-Child,
pubmed-meshheading:15888051-Child, Preschool,
pubmed-meshheading:15888051-Female,
pubmed-meshheading:15888051-Graft Rejection,
pubmed-meshheading:15888051-Graft Survival,
pubmed-meshheading:15888051-Humans,
pubmed-meshheading:15888051-Immunosuppressive Agents,
pubmed-meshheading:15888051-Infant,
pubmed-meshheading:15888051-Intestinal Diseases,
pubmed-meshheading:15888051-Intestines,
pubmed-meshheading:15888051-Lymphocyte Depletion,
pubmed-meshheading:15888051-Male,
pubmed-meshheading:15888051-Prednisone,
pubmed-meshheading:15888051-Rabbits,
pubmed-meshheading:15888051-Tacrolimus
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin).
|
| pubmed:affiliation |
Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Thomas E. Starzl Transplantation Institute, USA.
|
| pubmed:publicationType |
Journal Article
|